The short answer
Amylin is a 37-amino-acid hormone co-secreted with insulin from pancreatic beta cells. It slows gastric emptying, suppresses glucagon after meals and signals satiety through receptors in the area postrema. Amylin receptor agonists reproduce that signalling, and are being combined with GLP-1 agonists because the two pathways are largely independent.
Key facts
- Native hormone
- Amylin (islet amyloid polypeptide, IAPP)
- Length
- 37 amino acids
- Co-secreted with
- Insulin, from pancreatic beta cells
- Principal site of action
- Area postrema
- Clinical analogues
- Pramlintide (short-acting), cagrilintide (long-acting)
- Why combined with GLP-1
- Largely independent satiety pathways
What amylin does physiologically
Amylin is released alongside insulin in response to a meal and acts as a satiation signal. It slows the rate at which the stomach empties, suppresses inappropriate post-meal glucagon secretion, and acts centrally to reduce meal size. Its actions are complementary to insulin rather than duplicative: insulin manages glucose disposal, amylin manages the rate at which glucose arrives.
Where the receptor is
The amylin receptor is not a single conventional receptor but a complex formed when the calcitonin receptor associates with receptor activity-modifying proteins. The signalling relevant to satiety occurs largely in the area postrema, a circumventricular structure in the brainstem that sits outside the blood-brain barrier and is therefore directly exposed to circulating hormones. That anatomical position is why a peripherally administered amylin analogue can produce a central effect.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why native amylin could not be used as a drug
Human amylin aggregates readily into amyloid fibrils, which is both a formulation problem and the reason islet amyloid deposits appear in type 2 diabetes. Pramlintide, the first clinical amylin analogue, solved this with proline substitutions borrowed from rat amylin, which does not aggregate. Its short half-life required dosing with each meal. Cagrilintide is the long-acting successor engineered for weekly administration.
Why amylin and GLP-1 combine well
The two hormones reduce food intake through substantially different routes: GLP-1 largely via the hypothalamus and vagal afferents, amylin largely via the area postrema. Because the pathways are not the same, their effects add rather than saturate. This is the mechanistic argument behind CagriSema and amycretin, and it is a different strategy from the incretin multi-agonists, which stay within the glucagon receptor family.
How this fits the broader pipeline
There are now two distinct routes to increasing effect size beyond GLP-1 alone. One adds more incretin-family receptors (GIP, glucagon), as tirzepatide and retatrutide do. The other adds a non-incretin satiety hormone, which is what amylin combinations do. Both work, and they are not mutually exclusive.
Frequently asked questions
Is amylin an incretin?
No. Incretins are gut hormones released in response to nutrients that potentiate insulin secretion. Amylin is a beta-cell hormone co-secreted with insulin, with a different receptor and a different mechanism.
What is the area postrema?
A brainstem structure that sits outside the blood-brain barrier, which lets it detect circulating hormones directly. It is central to both satiety signalling and nausea.
Why does native human amylin form amyloid?
Its sequence is prone to aggregation. Clinical analogues substitute proline residues at the aggregation-prone positions to prevent it.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubChemPubChem · Pramlintide (CID 70691388)pubchem.ncbi.nlm.nih.gov
- RefCagriSema REDEFINE 1: Novo Nordiskprnewswire.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- Glucagon-Containing Dual Agonists: Survodutide and MazdutideWhy adding glucagon-receptor activity raises energy expenditure and targets liver fat. Survodutide and mazdutide trial status, and the counterintuitive logic.
- What the Data Says About Weight Regain After StoppingSTEP-1 extension found about two-thirds of lost weight returned within a year of stopping semaglutide. Meta-analyses put regain at roughly 0.8 kg per month.
- How to Read a Weight-Loss Trial Result ProperlyEstimands, populations, durations and discontinuation rates. Why CagriSema reports both 22.7% and 20.4%, and why headline percentages are not comparable.
- Oral Semaglutide vs OrforglipronBoth are tablets, only one is a peptide. Why oral semaglutide needs SNAC and a fasting window while orforglipron needs neither, and what that costs each.
- What Is Aleniglipron? The Second Oral Small-Molecule GLP-1Aleniglipron is an oral non-peptide GLP-1 agonist from Structure Therapeutics. ACCESS reported 12.1% at 36 weeks; ACCESS II reported 15.3% absolute at 44 weeks.